---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116082"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:15:49.299884+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock

## Summary
- Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.
- Each preferred share convertible into common at $1.00 per share (5% original issue discount).
- Investors agreed to vote Series F in favor of reverse stock split; Series G votes mirror proportions.
- Company filed certificates of designation and entered registration rights agreement for resale.
- A.G.P./Alliance Global Partners acted as placement agent with $1M cash fee plus expenses.

## SEC filing metadata
- accession: 0001104659-22-116082
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/0001104659-22-116082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/tm2230043d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116082
- JSON: https://secwatch.observer/filing/0001104659-22-116082.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116082.txt

## Key facts
- Material Agreements
  Hepion Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at gross proceeds of $20 million (effective 2022-11-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: gross proceeds of $20 million
  - Effective: 2022-11-04
  source text: On November 4, 2022, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), 1,900,000 shares of the Company’s Series F Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series F Preferred Stock ”), and 100,000 shares of the Company’s Series G Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series G Preferred Stock ,” and together with the Series F Preferred Stock, the “ Preferred Stock ”), at an offering price of $9.50 per share, representing a 5% original issue discount (“ OID ”) to the stated value of $10.00 per share, for gross proceeds of $20 million in the aggregate for the Offering, before the deduction of discounts, fees and offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/0001104659-22-116082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.